<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="109180">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01799564</url>
  </required_header>
  <id_info>
    <org_study_id>MPL4DRY</org_study_id>
    <nct_id>NCT01799564</nct_id>
  </id_info>
  <brief_title>Micropulse Laser for Geographic Atrophy</brief_title>
  <acronym>MPL4DRY</acronym>
  <official_title>A Phase I Study to Establish the Safety and Efficacy of Retinal Pigment Epithelium Micropulse Laser in Subjects With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de la Macula y la Retina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de la Macula y la Retina</source>
  <oversight_info>
    <authority>Spain: Comité Ético de Investigación Clínica</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Geographic atrophy (GA) causes the loss of the retinal pigment epithelium (RPE) cells in
      broad areas of the retina. The application of subthreshold micropulse laser spots in healthy
      RPE in the vicinity of the area of GA may restore the imbalance in survival factors caused
      by the disease (ie, the laser may decrease vascular endothelial growth factor and
      RPE-derived transforming growth factor beta, upregulation of pigment epithelium-derived
      factor). This may slow or even stop the enlargement of atrophy secondary to GA, and
      therefore, avoid further vision loss.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in area of atrophy as measured with fundus autofluorescence</measure>
    <time_frame>Change in area from baseline to week 48</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Geographic Atrophy</condition>
  <condition>Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Micropulse</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Micropulse laser will be applied to the inferior hemiretina next to the area of atrophy in a randomly selected eye in 1, 2 or 3 occasions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The fellow eye does not receive any treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Micropulse</intervention_name>
    <description>Between 1 and 3 sessions of micropulse laser will be applied in the inferior hemiretina of the randomly selected eye</description>
    <arm_group_label>Micropulse</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  GA &gt; 0.5 disk areas secondary to AMD in both eyes

          -  50 years or older

          -  The periphery of the atrophic lesions must demonstrate increased autofluorescence

          -  Best corrected visual acuity between 20/20 and 20/400 inclusive

          -  Clear ocular media

          -  Ability to provide informed consent and attend all study visits

        Exclusion Criteria:

          -  GA secondary to other causes aside from AMD

          -  Evidence of choroidal neovascularization in either eye

          -  Any prior treatment for AMD, aside from antioxidants

          -  Any other ocular condition that would progress in the study period and confound
             visual acuity assessment

          -  Any ocular or systemic medication known to be toxic to the lens, retina or optic
             nerve

          -  Presence of idiopathic or autoimmune-associated uveitis

          -  Any intraocular surgery 3 months of entry

          -  Any prior thermal laser in the macula

          -  History of vitrectomy, filtering surgery, corneal transplant or retinal detachment
             surgery

          -  Previous therapeutic radiation in the ocular region in either eye

          -  Any treatment with an investigational agent in the previous 60 days before study
             entry
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jordi Monés, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de la màcula i de la retina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jordi Monés, MD, PhD</last_name>
    <phone>+34935950155</phone>
    <email>info@institutmacularetina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marc Biarnés, OD, MPH</last_name>
    <phone>+34935950155</phone>
    <email>marcb@institutmacularetina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de la màcula i de la retina</name>
      <address>
        <city>Barcelona</city>
        <zip>08022</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Biarnés, OD, MPH</last_name>
      <phone>+34.935950155</phone>
      <email>marcmbp@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 25, 2013</lastchanged_date>
  <firstreceived_date>February 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institut de la Macula y la Retina</investigator_affiliation>
    <investigator_full_name>Jordi Mones</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Geographic atrophy</keyword>
  <keyword>Age-related macular degeneration</keyword>
  <keyword>Fundus autofluorescence</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Geographic Atrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
